Leader in pain therapeutics chooses PAS-X PROCESS DEVELOPMENT

Werum's software product ensures transparent management of starting materials in pharmaceuticals development at Grünenthal, Germany.

Grünenthal bundles all research and development activities at its campus in Aachen, Germany. Source: Grünenthal

Lüneburg, Germany, 29 May 2013 – The research-based international pharmaceutical company Grünenthal will deploy the PAS-X PROCESS DEVELOPMENT package. The group is leading in the field of pain therapies and invests more than a quarter of its revenues in research and development. Operating Werum's PAS-X PROCESS DEVELOPMENT, pharmaceutical and biotech companies can simplify and accelerate the modeling of manufacturing processes for pre-clinical and clinical studies. Grünenthal will initially install the package for substance tracking of clinical batches at its plant in Aachen, Germany.

“With PAS-X PROCESS DEVELOPMENT we are capable of tracking the use and consumption of all raw materials in pharmaceutical development,” says Dr. Martin Lueck, Vice President Head of Pharmaceutical Development & Drug Delivery at Grünenthal. “This enables us to further increase the efficiency of our development activities.”

In addition to PAS-X PROCESS DEVELOPMENT, Grünenthal will also deploy the PAS-X business functions MASTER BATCH RECORDS, WAREHOUSE MANAGEMENT and WEIGHING & DISPENSING.

About Grünenthal

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last remaining five research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. These investments amounted to about 26 percent of revenues in 2012. Grünenthal’s research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. The pharmaceutical group is intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies. Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries. Today, approx. 4,400 employees are working for the Grünenthal Group worldwide. In 2012, Grünenthal achieved revenues of € 973 mn. Additional information is available at www.grunenthal.com.